Global InformationViralytics information
 | This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (January 2016) |
| Industry | Biotechnology |
|---|---|
| Founded | 2006 |
| Headquarters | Sydney |
Key people | Paul A. Hopper Non-Executive chairman) Malcolm McColl (chief executive officer) Darren Shafren (Chief Scientific Officer) |
| Products | Cavatak, an oncylytic virus |
| Website | www |
Viralytics Ltd is an Australian biotechnology company working in the field of oncolytic viruses, that is, viruses that preferentially infect and kill cancer cells. The company's oncolytic virus product, called Cavatak, is currently in clinical trials in metastatic melanoma and other cancers. The drug was granted Orphan Drug status in advanced melanoma in December 2005.[2]
- ^ | type = Public company | traded_as = ASX: VLA
- ^ "Psiron's Cavatak received Orphan Drug Designation from the FDA" (PDF). asx.com.au. 21 December 2015. Retrieved 4 December 2015.